Last quarter, the company submitted its drug orforglipron, a new GLP-1 agonist, for obesity treatment in the United States and more than three dozen additional countries, with an expected domestic launch by mid-2026
26 luglio 2019 [citato 5 giugno 2024];2(4):e00082
Areas of expertise Prostate cancer Skin cancers Cutaneous lymphoma Urological cancers Dermatological oncology Melanoma Radiotherapy Chemotherapy Urological oncology Skin cancers Clinical oncology Prostate brachytherapy Professional memberships Articles by Mr Stephen Morris Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and szary syndrome: effect of specific prognostic markers on survival and development of a prognostic model Mogamulizumab versus vorinostat in previously treated cutaneous t-cell lymphoma (mavoric): an international, open-label, randomised, controlled phase 3 trial Evaluation of a belly board immobilisation device for rectal cancer patients receiving pre-operative chemoradiation
This makes it easier for patients and might help them follow their treatment better compared to medications that need more frequent doses
[3] Self-prescribing high doses without medical supervision is not advisable, as proper diagnosis and monitoring are essential
Synthetic analogues of 2-oxo acids discriminate metabolic contribution of the 2-oxoglutarate and 2-oxoadipate dehydrogenases in mammalian cells and tissues
